UNSPSC 51281601: Bluensomycin

This classification denotes an aminoglycoside antibiotic with the molecular formula C21H39N5O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LWV7PWE57U, chemically known as d-scyllo-inositol, o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1=>2)-o-5-deoxy-3-c-(hydroxymethyl)-alpha-l-lyxofuranosyl-(1=>2)-1-((aminoiminomethyl)amino)-1-deoxy-, 5-carbamate but generally known as bluensomycin, which bears US NIH Compound Identifier 65603. Bluensomycin most often comes in base and sulfate forms.

UNSPSC 51281601 Bluensomycin, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The two most recent opportunities tagged to this code diverge sharply from the product name: the Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets, while Seminole County, Florida solicited 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually. Neither opportunity is for Bluensomycin or closely related products. The Illinois award, posted August 28, 2026, was completed through an Invitation for Bid process with a 12-month initial term and two 1-year renewal options; the Seminole County IFB, posted June 30, 2026, sought quarterly deliveries to a single community health facility with a two-year initial term and one-year renewal option, potentially funded through FEMA. Both issuing bodies are health or public-safety-focused agencies procuring pharmaceutical or medical products with established cooperative purchasing or piggyback vehicles.

The code shows activity in Florida and Illinois, with no visible concentration or repeat-buyer pattern in the recent record. The mismatch between the code's nominal scope (Bluensomycin) and the actual products being solicited (antibiotics, opioid-reversal agents, drug deactivation systems) suggests either miscoding by the procurement offices or that state and local buyers are using this commodity code as a catch-all for pharmaceutical supply orders outside their primary classification schemes. Vendors pursuing pharmaceutical supply contracts with state health departments or county public-health agencies should monitor this code for opportunities but should not rely on the product name as a reliable filter — direct monitoring of health department and county procurement portals in target geographies will be more productive.